louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02110940: The Effect of Neurodynamic Mobilization Exercise on Lower Limb Pain in Patients With Rheumatoid Arthritis.
Official title: The Effect of Neural Mobilization Exercise on Lower Limb Pain in Patients With Rheumatoid Arthritis.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rheumatoid Arthritis
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
First posted: 2014-04-10
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This clinical trial is the first study to apply neurodynamic mobilization, a nervous system specific therapeutic exercise, on patients with rheumatoid arthritis(RA). Objective of the study is to find out the effect of neurodynamic mobilization for joint inflammation in patients with RA.

Detailed description: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by generalized joints inflammation. With increasing investigation on the pathology, the treatment focus on the conditions shifted from a musculoskeletal point of view to a systemic approach. The awareness of holistic treatment was also increased.

Latest studies have found out the neurogenic inflammatory mechanism played an important role in the inflammatory process of RA, the pathological changes of neural tissues in RA were also noted.

This clinical trial is the first study to apply neurodynamic mobilization, a nervous system specific therapeutic exercise, on patients with RA. Objective of the study is to find out the effect of neurodynamic mobilization for joint inflammation in patients with RA.

Population Adults who are diagnosed with Rheumatoid Arthritis.

Intervention Neurodynamic Exercise

Comparison Standard conservative physiotherapy protocol

Outcome Rheumatoid Arthritis Pain Scale (RAPS) C-reactive protein (CRP) test

Eligibility criteria: Inclusion Criteria:

* The inclusion criteria was considered as patients with rheumatoid arthritis; presence of inflammatory condition on the joints on upper and / or lower limbs; Rheumatoid Arthritis Pain Scale (RAPS) at least 10 points during activities of daily living; and adults (\> 18 years of age) in either gender.

Exclusion Criteria:

* The exclusion criteria are: acute joint pain, physiotherapy or joint injections in the previous 3 months; change in corticosteroids in the previous month; and change in disease-modifying antirheumatic drugs in the previous 3 months; subjects with poor balance or significant pain which neurodynamic mobilization is unable to perform.

Primary outcomes:
measure: Rheumatoid Arthritis Pain Scale (RAPS)
timeFrame: 8 weeks
Secondary outcomes:
measure: C-reactive protein (CRP) test
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: The Hong Kong Polytechnic University
Study officials:
name: Chi Ngai Lo, Master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05860140: Preventing Malnutrition Among Older Adults
Official title: Prevention and Treatment of Malnutrition Among Home-living Older Adults Over 65 Years.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Malnutrition
Keywords: older adults
Disease-related malnutrition
Educational video
Lead sponsor: Nord University
Sponsor class: OTHER
First posted: 2023-05-16
Enrollment: 250
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This project aims to explore whether access to a digital education video can improve the nutritional situation of home-living older adults after being discharged from the hospital.


Eligibility criteria: Inclusion Criteria:

* Orthopedic and surgical in bedded patient patients in a selected regional hospital in Norway.
* Over 65 years old. Have their home address in one of nine selected municipalities in Nordland county.
* home living and due to return home after discharge directly from the hospital or after a short-term training stay at a training centre before returning home.
* Could read and understand Norwegian.
* Have consent competence.
* Have a Body mass index less than 24.

Exclusion Criteria:

* Patients patients only receiving liquid diet such as tube feeding
* terminal-ill patients

Primary outcomes:
measure: Health related quality of life Using Rand 36 Questionnaire
timeFrame: Change in Health related quality of life Using Rand 36 Questionnaire after 3 months
Secondary outcomes:
measure: Body fat
timeFrame: Change in Body mass index after 3 months
measure: Readmissions to hospital after discharge from the hospital
timeFrame: Registration of Readmissions 3 months after
measure: Muscle Strength
timeFrame: Change in Hand Grip Strength (muscle strenght) after 3 months
measure: The mid-arm circumference
timeFrame: Change in The mid-arm circumference after 3 months
measure: Subcutaneous fat
timeFrame: Change in Subcutaneous fat after 3 months
measure: Muscle protein mass
timeFrame: Change in Muscle protein mass after 3 months
Other outcomes:
Locations:
city: Bodø
country: Norway
facility: Monica Christin Hansen
Study officials:
References:
Clinical trial NCT03591640: The Validity of Kleinhauer Betke in Women With Known Hemoglobinopathy for Fetal-maternal Hemorrhage
Official title: The Validity of Kleinhauer Betke in Women With Known Hemoglobinopathy for Fetal-maternal Hemorrhage
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fetal-Maternal Hemorrhage
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2018-07-19
Enrollment: 27
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study is to determine the validity of Kleinhauer Betke in women with known hemoglobinopathy for fetal-maternal hemorrhage.


Eligibility criteria: Inclusion Criteria:

* Pregnant with singleton fetus
* Gestational age 34-42
* With or without known hemoglobinopathy

Exclusion Criteria:

* Known risk factor for fetal maternal hemorrhage

Primary outcomes:
measure: Validity of Kleinhauer Betke test in Pregnant Women
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hille Yaffe Medical Center
Study officials:
affiliation: Hillel Yaffe Medical Center
name: Rinat Gabbay-Benziv, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01944540: Brief Title : Optimized Endoscopic Submucosal Dissection With Snaring for Colorectal Neoplasm
Official title: Comparison of Coventional Endoscopic Submucosal Dissection and Optimized Endoscopic Submucosal Dissection With Snaring for Colorectal Neoplasm
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Colorectal Neoplasms
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2013-09-17
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is aimed to analyze the outcomes after conventional endoscopic submucosal dissection (ESD) and optimized ESD with snaring (oESD-S) for colorectal neoplasm that is more than 20 mm in diameter of laterllay spreading tumor or flat elevated lesion without stalk.

Optimized ESD with snaring means submucosal dissection followed by snaring when narrowed circumference of the remained submucosal tissue beneath the lesion is less than 5 mm in diameter with snaring, then resected by using an electric current.

The investigators expect optimized ESD with snaring can provide more time-saving procedure with comparable en-bloc resection rate and perforation rate, when compared with the conventional ESD method.


Eligibility criteria: Inclusion Criteria:

* colorectal laterally spreading tumor that is more than 20 mm in diameter
* other elevated or flat colorectal neoplasm without stalk, that is more than 20 mm in diameter

Exclusion Criteria:

* colorectal neoplasms that are proven or suspected to be invaded more than submucosal invasion
* colorectal neoplasms that have severe fibrosis beneath the target lesion
* patient's refusal to participate this study
* less than 18 years old
* subjects who cannot consent voluntarily due to the communication difficulty

Primary outcomes:
measure: procedure time
timeFrame: 8 months
measure: En Bloc resection rate
timeFrame: 8 months
Secondary outcomes:
measure: histologic complete resection rate
timeFrame: 8 months
measure: complication rate
timeFrame: 8 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center, University of Ulsan College of Medicine
Study officials:
affiliation: Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
name: Jeong-Sik Byoen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bae JH, Yang DH, Lee S, Soh JS, Lee S, Lee HS, Lee HJ, Park SH, Kim KJ, Ye BD, Myung SJ, Yang SK, Byeon JS. Optimized hybrid endoscopic submucosal dissection for colorectal tumors: a randomized controlled trial. Gastrointest Endosc. 2016 Mar;83(3):584-92. doi: 10.1016/j.gie.2015.06.057. Epub 2015 Aug 28.
Clinical trial NCT04101240: Anemia and Red Blood Cells Transfusion in Oncological Surgery
Official title: Impact of Perioperative Anemia and Red Blood Cells Transfusion on Post-operative Complications After Oncological Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Anemia
Surgery
Oncology
Keywords: red blood cells transfusion
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2019-09-24
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adults admitted to the intensive care unit (ICU) after oncologic surgery from January 2017 to December 2018 are eligible. The following types of surgery for cancer or metastasis resection with a high risk of bleeding are eligible: thoracic, abdominal, neurosurgery, gynecologic, urologic, otorhinolaryngology or spinal surgery.

Brief summary: Oncologic patients experience anemia and anemia is associated with poor prognosis. Transfusion is associated with adverse events, and equipoise remains on the optimal transfusion strategy in oncologic patients in surgical setting. The primary objective of this study is to determine the impact of anemia and red blood cells (RBC) transfusion on post-operative complications and mortality.

Detailed description: Between 36 and 75% of oncologic patients experience anemia and anemia is associated with poor prognosis. Up to 40% of surgical oncologic patients receive red blood cells (RBC). However, transfusion is associated with adverse events, and equipoise remains on the optimal transfusion strategy in oncologic patients in surgical setting. The primary objective of this study is to determine the impact of anemia and red blood cells (RBC) transfusion on post-operative complications and mortality. This is a retrospective, single center study. All adults admitted to the intensive care unit (ICU) after oncologic surgery within the study period are eligible.

Eligibility criteria: Inclusion Criteria:

* Surgery for cancer
* Admission to intensive care

Exclusion Criteria:

* no consent

Primary outcomes:
measure: Number of mortality or any respiratory, cardiac, renal, thromboembolic, infectious and/or hemorrhagic post operative complications
timeFrame: 30 DAYS (hospital discharge)
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest, hôpital de la Cavale Blanche
Study officials:
affiliation: Service de Médecine Intensive Réanimation
name: Cécile AUBRON, PU PH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05255640: OUTCOME OF PATIENTS ADMITTED WITH ACUTE LOWER EXTREMITY ISCHEMIA
Official title: MULTICENTER OBSERVATIONAL STUDY OF THE OUTCOME OF PATIENTS ADMITTED WITH ACUTE LOWER EXTREMITY ISCHEMIA
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Ischemia of Lower Limb
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2022-02-24
Enrollment: 176
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with lower limb ischemia

Brief summary: Acute ischemia of the lower limb (AMI) is a life-threatening emergency that threatens the functional prognosis of the limb. Depending on the clinical presentation and the anatomy of the patient, several therapeutic approaches can be considered: open surgery, endovascular surgery, hybrid surgery or amputation if revascularization is not feasible. The data in the current literature do not allow to clearly establish which therapeutic approach is the most adapted to the patient.


Eligibility criteria: Inclusion Criteria:

* Age greater than 18 years, regardless of gender.
* Diagnosis of AMI defined according to the Rutherford classification (2). AMI may involve one or both lower limbs.
* Be able to understand and give free and informed consent (non-opposition) to participate in the study
* To be affiliated to the social security system
* Not to object to participating in the study (collection of non-objection)

Exclusion Criteria:

* Voluntary discharge of the patient: opposition to the use of the data (withdrawal of the non-objection)
* Termination of the study by decision of the sponsor or investigator.

Primary outcomes:
measure: survival
timeFrame: 30 days
measure: survival
timeFrame: 90 days
Secondary outcomes:
Other outcomes:
Locations:
city: Besançon
country: France
facility: Besançon university hospital
city: Bordeaux
country: France
facility: Bordeaux University Hospital
city: Brest
country: France
facility: Brest University Hospital
city: Dijon
country: France
facility: Dijon University Hospital
city: Lyon
country: France
facility: Lyon University Hospital
city: Nancy
country: France
facility: Nancu University Hospital
city: Nantes
country: France
facility: Nantes University Hospital
city: Nice
country: France
facility: Nice University Hospital
city: Paris
country: France
facility: APHP - Hôpital Mondor
city: Paris
country: France
facility: APHP- Ambroise Paré
city: Paris
country: France
facility: APHP- Hôpital Bichat
city: Paris
country: France
facility: APHP- Hôpital Européen Georges Pompidou
city: Reims
country: France
facility: Reims University Hospital
city: Strasbourg
country: France
facility: Strasbourg University Hospital
Study officials:
References:
Clinical trial NCT00342940: Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
Official title: A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, When Administered to Non-Elderly Adult and Elderly Subjects
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Influenza
Keywords: influenza
influenza vaccine
flu
vaccination
immunogenicity
Lead sponsor: Novartis
Sponsor class: INDUSTRY
Collaborators: name: Novartis Vaccines
First posted: 2006-06-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The present study aims to evaluate safety and immunogenicity of one dose of a commercially available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, in non-elderly adult and elderly subjects.


Eligibility criteria: Inclusion Criteria:

* Male and female subjects 18 years of age or older

Exclusion Criteria:

* any auto-immune disease or other serious acute, chronic or progressive disease
* hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine
* known or suspected (or high risk of developing) impairment/alteration of immune function
* within the past 7 days any acute disease or infections requiring systemic antibiotic or antiviral therapy
* history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine

Primary outcomes:
measure: CHMP criteria for evaluation of flu vaccines e.g Seroprotection, GMR's and Seroconversion rate at day 21 following vaccination
Secondary outcomes:
measure: Number and percentage of subjects with at least one local reaction between Day 0 and Day 3 after vaccine injection.
measure: Number and percentage of subjects with at least one systemic reaction between Day 0 and Day 3 after vaccine injection.
measure: Number and percentage of subjects with at least one adverse event between Day 0 and the study termination visit (Day 21, window: 20-24).
Other outcomes:
Locations:
city: Slough
country: United Kingdom
facility: Chiltern International Limited , Chiltern Place, Upton Road
Study officials:
affiliation: Novartis
name: Novartis Vaccines Drug Information Services
role: STUDY_CHAIR
References:
Clinical trial NCT01657240: Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis
Official title: Phase 3 Clinical Trial to Evaluate the Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Allergic Conjunctivitis
Lead sponsor: Laboratorios Sophia S.A de C.V.
Sponsor class: INDUSTRY
First posted: 2012-08-06
Enrollment: 0
Sex: ALL
Minimum age (years): 6
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the clinical efficacy of the ophthalmic solution PRO-118 compared with olopatadine hydrochloride ophthalmic solution in allergic conjunctivitis.

Detailed description: Allergic conjunctivitis is inflammation of the tissue lining the eyelids (conjunctiva) due to a reaction from allergy-causing substances. The main aim in allergic conjunctivitis is to improve the quality of life in these patients. Antihistaminic medication is commonly used to treat allergic conjunctivitis symptoms. The aim of the study is to compare the clinical efficacy of two ophthalmic solutions containing each one an antihistaminic drug.

A phase III randomized double-blind clinical trial will be conducted to evaluate efficacy of the ophthalmic solution PRO-118 compared with olopatadine hydrochloride ophthalmic solution in allergic conjunctivitis. Patients will be randomized to receive one of the treatments for 21 days. Efficacy endpoints will be measured at baseline and at 21 days after treatment.

Eligibility criteria: Inclusion Criteria:

* Provide informed consent
* Allergic conjunctivitis diagnosis
* Both genders
* Age between 6 and 60 years
* Patients with no treatment 2 years prior to study inclusion

Exclusion Criteria:

* Patients with one blind eye
* Visual acuity \< 20/40 in any eye
* Patients with any active ocular disease that would interfere with study interpretation
* Patients in treatment with any medication that could interfere with the study, contraindication of any medication used in the protocol
* Patients with: diabetes mellitus, rheumatoid arthritis, hypertension, or any type of cancer
* Patients with history of hypersensitivity or contraindication for any drug used in the study
* Patients receiving systemic or topical treatment based on antihistamines, corticosteroids or immunomodulators
* Pregnant patients, at risk of pregnancy or breastfeeding
* Patients without birth control treatment
* Patients who had participated in any clinical trial in the last 90 days

Primary outcomes:
measure: conjunctival hyperemia
timeFrame: day 21
Secondary outcomes:
measure: epiphora
timeFrame: day 21
Other outcomes:
measure: green lissamine dye
timeFrame: day 21
measure: fluorescein dye
timeFrame: day 21
Locations:
Study officials:
References:
Clinical trial NCT02014740: Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes
Official title: Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Type 2 Diabetes
Overweight
Obesity
Keywords: Epicardial fat
Type 2 diabetes
Obesity
GLP-1 analogs
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2013-12-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be associated with poor sugar control. Liraglutide is an injectable prescription medicine that can improve blood sugar control in adults with type 2 diabetes.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes, as defined by ADA criteria
* HbA1c \< 8% measured at least 1 month prior to this study
* BMI ≥27 kg/m2
* Pre-treatment with Metformin
* Age \> 18 and \< 65 years old

Exclusion Criteria:

* • Known contra-indications to Liraglutide, such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of MEN, in accordance with risks and safety information included in the latest updated Prescribing Information for Victoza®

  * Type 1 diabetes, as defined by American Diabetes Association (ADA) criteria
  * Insulin dependent or treated type 2 diabetes
  * Current use of other injectable incretins
  * History of diabetes ketoacidosis
  * Advanced Chronic Kidney Disease, as defined by Glomerular Filtration Rate (GFR) \< 30 mL/min/1.73m2
  * Clinical signs or symptoms of New York Heart Association (NYHA) class III-IV heart failure
  * Clinical or laboratory evidences of chronic active liver diseases
  * Acute or chronic infective diseases
  * Cancer or chemotherapy
  * Current use of systemic corticosteroids or in the 3 months prior this study
  * Known or suspected allergy to Liraglutide, excipients, or related products
  * Pregnant, breast-feeding or the intention of becoming pregnant
  * Females of childbearing potential who are not using adequate contraceptive methods

Primary outcomes:
measure: Echocardiographic Epicardial Fat Thickness
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
References:
citation: Iacobellis G, Mohseni M, Bianco SD, Banga PK. Liraglutide causes large and rapid epicardial fat reduction. Obesity (Silver Spring). 2017 Feb;25(2):311-316. doi: 10.1002/oby.21718.